Evidence for safety and efficacy of risedronate in men with osteoporosis over 4years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

Steven Boonen, Roman S. Lorenc, Dietrich Wenderoth, Karen J. Stoner, Rachelle Eusebio, Eric Orwoll

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A 2-year, randomized, double-blind, placebo-controlled study in men with osteoporosis demonstrated that treatment with risedronate 35. mg once a week significantly decreased bone turnover markers (BTMs) and increased bone mineral density (BMD). This study was extended to include a 2-year, open-label extension to continue to assess the safety and efficacy of risedronate in men with osteoporosis. In the open-label extension, all patients received risedronate 35. mg once a week, and 1000. mg elemental calcium and 400 to 500. IU vitamin D daily for up to 2. years. The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results. BMD, BTMs, and the incidence of new vertebral fractures were also assessed. A total of 218 (of 284) patients enrolled in the open-label extension. Risedronate continued to produce significant increases in lumbar spine BMD from baseline (7.87%) in the group of patients who took it for 4. years. Risedronate produced significant increases in lumbar spine BMD from baseline (6.27%) in the former placebo group who took it for 2. years during the open-label extension. Few new vertebral and clinical fractures occurred during the study. There were no significant differences in BTMs between the two groups at months 36 and 48. Incidences of any upper GI adverse events during the extension were low and similar in the two groups; however, the percent of moderate to severe events were higher (8% versus 2%) in the group that received placebo prior to the extension. Safety results continued to show that risedronate was well-tolerated in men with osteoporosis. Patients who received risedronate 35. mg once a week for 2. years in the open-label extension study showed similar safety and efficacy results compared with those who received risedronate treatment in the first 2 double-blind years of the study. Patients who received risedronate for 4. years in total showed similar safety and efficacy to that observed in women with postmenopausal osteoporosis treated with risedronate for 4. years. (ClinicalTrials.gov Identifier number: NCT00619957).

Original languageEnglish (US)
Pages (from-to)383-388
Number of pages6
JournalBone
Volume51
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Osteoporosis
Placebos
Safety
Bone Density
Bone Remodeling
Therapeutics
Spine
Risedronate Sodium
Postmenopausal Osteoporosis
Vital Signs
Incidence
Double-Blind Method
Vitamin D
Physical Examination
Calcium

Keywords

  • Bisphosphonates
  • Bone mineral density
  • Bone turnover markers
  • Male osteoporosis
  • Risedronate

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4years of treatment : Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. / Boonen, Steven; Lorenc, Roman S.; Wenderoth, Dietrich; Stoner, Karen J.; Eusebio, Rachelle; Orwoll, Eric.

In: Bone, Vol. 51, No. 3, 09.2012, p. 383-388.

Research output: Contribution to journalArticle

@article{cf8c6d09a18a4d2299e420a99d7df3e0,
title = "Evidence for safety and efficacy of risedronate in men with osteoporosis over 4years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study",
abstract = "A 2-year, randomized, double-blind, placebo-controlled study in men with osteoporosis demonstrated that treatment with risedronate 35. mg once a week significantly decreased bone turnover markers (BTMs) and increased bone mineral density (BMD). This study was extended to include a 2-year, open-label extension to continue to assess the safety and efficacy of risedronate in men with osteoporosis. In the open-label extension, all patients received risedronate 35. mg once a week, and 1000. mg elemental calcium and 400 to 500. IU vitamin D daily for up to 2. years. The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results. BMD, BTMs, and the incidence of new vertebral fractures were also assessed. A total of 218 (of 284) patients enrolled in the open-label extension. Risedronate continued to produce significant increases in lumbar spine BMD from baseline (7.87{\%}) in the group of patients who took it for 4. years. Risedronate produced significant increases in lumbar spine BMD from baseline (6.27{\%}) in the former placebo group who took it for 2. years during the open-label extension. Few new vertebral and clinical fractures occurred during the study. There were no significant differences in BTMs between the two groups at months 36 and 48. Incidences of any upper GI adverse events during the extension were low and similar in the two groups; however, the percent of moderate to severe events were higher (8{\%} versus 2{\%}) in the group that received placebo prior to the extension. Safety results continued to show that risedronate was well-tolerated in men with osteoporosis. Patients who received risedronate 35. mg once a week for 2. years in the open-label extension study showed similar safety and efficacy results compared with those who received risedronate treatment in the first 2 double-blind years of the study. Patients who received risedronate for 4. years in total showed similar safety and efficacy to that observed in women with postmenopausal osteoporosis treated with risedronate for 4. years. (ClinicalTrials.gov Identifier number: NCT00619957).",
keywords = "Bisphosphonates, Bone mineral density, Bone turnover markers, Male osteoporosis, Risedronate",
author = "Steven Boonen and Lorenc, {Roman S.} and Dietrich Wenderoth and Stoner, {Karen J.} and Rachelle Eusebio and Eric Orwoll",
year = "2012",
month = "9",
doi = "10.1016/j.bone.2012.06.016",
language = "English (US)",
volume = "51",
pages = "383--388",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Evidence for safety and efficacy of risedronate in men with osteoporosis over 4years of treatment

T2 - Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

AU - Boonen, Steven

AU - Lorenc, Roman S.

AU - Wenderoth, Dietrich

AU - Stoner, Karen J.

AU - Eusebio, Rachelle

AU - Orwoll, Eric

PY - 2012/9

Y1 - 2012/9

N2 - A 2-year, randomized, double-blind, placebo-controlled study in men with osteoporosis demonstrated that treatment with risedronate 35. mg once a week significantly decreased bone turnover markers (BTMs) and increased bone mineral density (BMD). This study was extended to include a 2-year, open-label extension to continue to assess the safety and efficacy of risedronate in men with osteoporosis. In the open-label extension, all patients received risedronate 35. mg once a week, and 1000. mg elemental calcium and 400 to 500. IU vitamin D daily for up to 2. years. The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results. BMD, BTMs, and the incidence of new vertebral fractures were also assessed. A total of 218 (of 284) patients enrolled in the open-label extension. Risedronate continued to produce significant increases in lumbar spine BMD from baseline (7.87%) in the group of patients who took it for 4. years. Risedronate produced significant increases in lumbar spine BMD from baseline (6.27%) in the former placebo group who took it for 2. years during the open-label extension. Few new vertebral and clinical fractures occurred during the study. There were no significant differences in BTMs between the two groups at months 36 and 48. Incidences of any upper GI adverse events during the extension were low and similar in the two groups; however, the percent of moderate to severe events were higher (8% versus 2%) in the group that received placebo prior to the extension. Safety results continued to show that risedronate was well-tolerated in men with osteoporosis. Patients who received risedronate 35. mg once a week for 2. years in the open-label extension study showed similar safety and efficacy results compared with those who received risedronate treatment in the first 2 double-blind years of the study. Patients who received risedronate for 4. years in total showed similar safety and efficacy to that observed in women with postmenopausal osteoporosis treated with risedronate for 4. years. (ClinicalTrials.gov Identifier number: NCT00619957).

AB - A 2-year, randomized, double-blind, placebo-controlled study in men with osteoporosis demonstrated that treatment with risedronate 35. mg once a week significantly decreased bone turnover markers (BTMs) and increased bone mineral density (BMD). This study was extended to include a 2-year, open-label extension to continue to assess the safety and efficacy of risedronate in men with osteoporosis. In the open-label extension, all patients received risedronate 35. mg once a week, and 1000. mg elemental calcium and 400 to 500. IU vitamin D daily for up to 2. years. The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results. BMD, BTMs, and the incidence of new vertebral fractures were also assessed. A total of 218 (of 284) patients enrolled in the open-label extension. Risedronate continued to produce significant increases in lumbar spine BMD from baseline (7.87%) in the group of patients who took it for 4. years. Risedronate produced significant increases in lumbar spine BMD from baseline (6.27%) in the former placebo group who took it for 2. years during the open-label extension. Few new vertebral and clinical fractures occurred during the study. There were no significant differences in BTMs between the two groups at months 36 and 48. Incidences of any upper GI adverse events during the extension were low and similar in the two groups; however, the percent of moderate to severe events were higher (8% versus 2%) in the group that received placebo prior to the extension. Safety results continued to show that risedronate was well-tolerated in men with osteoporosis. Patients who received risedronate 35. mg once a week for 2. years in the open-label extension study showed similar safety and efficacy results compared with those who received risedronate treatment in the first 2 double-blind years of the study. Patients who received risedronate for 4. years in total showed similar safety and efficacy to that observed in women with postmenopausal osteoporosis treated with risedronate for 4. years. (ClinicalTrials.gov Identifier number: NCT00619957).

KW - Bisphosphonates

KW - Bone mineral density

KW - Bone turnover markers

KW - Male osteoporosis

KW - Risedronate

UR - http://www.scopus.com/inward/record.url?scp=84863820744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863820744&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2012.06.016

DO - 10.1016/j.bone.2012.06.016

M3 - Article

C2 - 22750403

AN - SCOPUS:84863820744

VL - 51

SP - 383

EP - 388

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -